Prevention of orthopedic device-associated osteomyelitis using oxacillin-containing biomineral-binding liposomes

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3169-3179

  Liu, Xin Ming ^a   Zhang, Yijia ^a   Chen, Fu ^a   Khutsishvili, Irine ^a   Fehringer, Edward V ^b   Marky, Luis A ^a   Bayles, Kenneth W ^c   Wang, Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

bisphosphonates; liposomes; orthopaedic implant; osteomyelitis; oxacillin

Indexed keywords

ALENDRONATE TRI(ETHYLENE GLYCOL)CHOLESTEROL CONJUGATE; BIOMINERAL BINDING LIPOSOME; CHOLESTEROL; HYDROXYAPATITE; LIPID; LIPOSOME; OXACILLIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BINDING AFFINITY; BIOFILM; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; IN VITRO STUDY; LIPOSOMAL DELIVERY; NONHUMAN; ORTHOPEDIC EQUIPMENT; OSTEOMYELITIS; PHASE TRANSITION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; THERMODYNAMICS; THERMOSTABILITY;

BIOFILMS; CALORIMETRY, DIFFERENTIAL SCANNING; CYCLOADDITION REACTION; EXCIPIENTS; KINETICS; LIPOSOMES; ORTHOPEDIC FIXATION DEVICES; ORTHOPEDICS; OSTEOMYELITIS; OXACILLIN; PHASE TRANSITION; PROSTHESES AND IMPLANTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THERMODYNAMICS;

EID: 84867878089     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0812-7     Document Type: Article

References (41)

1. Wu P, Grainger DW. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials. 2006;27:2450-67.
2. Harris LG, Richards RG. Staphylococci and implant surfaces: a review. Injury. 2006;37 Suppl 2:S3-14.
3. Mader JT, Landon GC, Calhoun J. Antimicrobial treatment of osteomyelitis. Clin Orthop Relat Res. 1993;87-95.
4. Ostermann PA, Henry SL, Seligson D. Timing of wound closure in severe compound fractures. Orthopedics. 1994;17:397-9.
5. Price JS, Tencer AF, Arm DM, Bohach GA. Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res. 1996;30:281-6.
6. Seligson D, Klemm K. Adult posttraumatic osteomyelitis of the tibial diaphysis of the tibial shaft. Clin Orthop Relat Res. 1999;30-6.
7. Hetrick EM, Schoenfisch MH. Reducing implant-related infections: active release strategies. Chem Soc Rev. 2006;35:780-9.
8. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008;23:984-91.
9. Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am. 2009;91:128-33.
10. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med. 1997;336:999-1007.
11. Diaz-Rodriguez P, Landin M, Rey-Rico A, Couceiro J, Coenye T, Gonzalez P, et al. Bio-inspired porous SiC ceramics loaded with vancomycin for preventing MRSA infections. J Mater Sci Mater Med. 22:339-47.
12. El-Husseiny M, Patel S, MacFarlane RJ, Haddad FS. Biodegradable antibiotic delivery systems. J Bone Joint Surg Br. 93:151-7.
13. Tanaka KS, Houghton TJ, Kang T, Dietrich E, Delorme D, Ferreira SS, et al. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. Bioorg Med Chem. 2008;16:9217-29.
14. Takahashi T, Yokogawa K, Sakura N, Nomura M, Kobayashi S, Miyamoto K. Bone-targeting of quinolones conjugated with an acidic oligopeptide. Pharm Res. 2008;25:2881-8.
15. Schmidmaier G, Lucke M, Wildemann B, Haas NP, Raschke M. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury. 2006;37 Suppl 2:S105-12.
16. Bernthal NM, Stavrakis AI, Billi F, Cho JS, Kremen TJ, Simon SI, et al. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One.5:e12580.
17. Hein CD, Liu XM, Wang D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res. 2008;25:2216-30.
18. Khoo X, O'Toole GA, Nair SA, Snyder BD, Kenan DJ, Grinstaff MW. Staphylococcus aureus resistance on titanium coated with multivalent PEGylated-peptides. Biomaterials. 31:9285-92.
19. Yoshinari M, Kato T, Matsuzaka K, Hayakawa T, Shiba K. Prevention of biofilm formation on titanium surfaces modified with conjugated molecules comprised of antimicrobial and titanium-binding peptides. Biofouling. 26:103-10.
20. Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology. 8th ed. Saunders Elsevier; 2007. p. 810-811.
21. Liu XM, Lee HT, Reinhardt RA, Marky LA, Wang D. Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity. J Control Release. 2007;122:54-62.
22. Liu XM, Thakur A, Wang D. Efficient synthesis of linear multifunctional poly(ethylene glycol) by copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition. Biomacromolecules. 2007;8:2653-8.
23. Marky LA, Breslauer KJ. Calculating thermodynamic data for transitions of any molecularity from equilibrium melting curves. Biopolymers. 1987;26:1601-20.
24. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect Immun. 1995;63:3373-80.
25. Jett BD, Hatter KL, Huycke MM, Gilmore MS. Simplified agar plate method for quantifying viable bacteria. Biotechniques. 1997;23:648-50.
26. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71-97.
27. Gaitanis A, Staal S. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 624:385-92.
28. Ohvo-Rekila H, Ramstedt B, Leppimaki P, Slotte JP. Cholesterol interactions with phospholipids in membranes. Prog Lipid Res. 2002;41:66-97.
29. Zhang S, Gangal G, Uludag H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev. 2007;36:507-31.
30. Wang D, Miller SC, Kopeček J. Targeted drug delivery for musculoskeletal diseases. Adv Drug Deliv Rev. 2005;57:935-7.
31. Pan H, Sima M, Kopečková P, Wu K, Gao S, Liu J, et al. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. Mol Pharm. 2008;5:548-58.
32. Wang D, Miller S, Sima M, Kopečková P, Kopeček J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem. 2003;14:853-9.
33. Liu XM, Wiswall AT, Rutledge JE, Akhter MP, Cullen DM, Reinhardt RA, et al. Osteotropic beta-cyclodextrin for local bone regeneration. Biomaterials. 2008;29:1686-92.
34. Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001;40:2004-21.
35. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective ligation of azides and terminal alkynes. Angew Chem Int Ed Engl. 2002;41:2596-9.
36. Anada T, Takeda Y, Honda Y, Sakurai K, Suzuki O. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorg Med Chem Lett. 2009;19:4148-50.
37. Hengst V, Oussoren C, Kissel T, Storm G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm. 2007;331:224-7.
38. Wang G, Babadagli ME, Uludag H. Bisphosphonate-derivatized liposomes to control drug release from collagen/hydroxyapatite scaffolds. Mol Pharm. 8:1025-34.
39. Bolean M, Simao AM, Favarin BZ, Millan JL, Ciancaglini P. The effect of cholesterol on the reconstitution of alkaline phosphatase into liposomes. Biophys Chem. 152:74-9.
40. Halling KK, Slotte JP. Membrane properties of plant sterols in phospholipid bilayers as determined by differential scanning calorimetry, resonance energy transfer and detergent-induced solubilization. Biochim Biophys Acta. 2004;1664:161-71.
41. Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 51 Suppl 2:S183-97.